The Acne Treatment Market to grow based on digitized impertinence at a CAGR of 6%
The Acne Treatment Market is expected to grow, at a CAGR of 5.9% between 2021-2031. Digital health is into occupation of a noteworthy position in our lives, thereby rendering it a significant tool in the medical device trends going forward. This would be the overall outlook of the healthcare vertical in the forecast period.
As per Persistence Market Research’s latest revised industry analysis, the global acne treatment market was valued at over US$ 5.8 Bn in 2020, and is expected to exhibit a CAGR of close to 6% over the forecast period (2021-2031)
In the United States, acne affects approximately 50 million people annually. Increasing rate of skin diseases is one of the major factors boosting market growth globally. Acne is most commonly observed among teenagers, but can also be observed in people across all age groups.
According to the American Academy of Dermatology Association, over 85% of the population between the ages 12 and 24 have suffered from minor acne at least once or twice, and this may continue into individuals in their ‘30s and ‘40s
Get Free Sample Of Acne Treatment Market@ https://www.persistencemarketresearch.com/samples/5279
Significant prevalence of acne has led to increased awareness of considering skin treatment. This, in turn, is expected to fuel demand for acne treatment products. As new drugs and treatments are required to replace older methods such as antibiotics, acne research & development generates avenues and opportunities for players in the market. As a result, various industry players are receiving approvals from regulatory authorities.
Some of the recent approvals include AKLIEF (trifarotene) 0.005% cream (October 2019, Galderma SA), ARAZLO (tazarotene) Lotion, 0.045% (Bausch Health Companies Inc., December 2019), and ACZONE (DAPSONE) GEL (September 2019, Almirall S.A.). Thus, growing approvals support a positive outlook for continued healthy market growth.
Company Profile’s:
- Galderma S.A.
- Lumenis Ltd
- Alma Lasers, Sisram Medical Company
- Cutera Inc.
- Almirall, S.A
- Johnson & Johnson Services Inc.
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd.
- Stiefel Laboratories, a GSK Company
- Candela Medical
Switch Over To The “Methodology” Tab@ https://www.persistencemarketresearch.com/methodology/5279
Key Takeaways from Market Study
- By treatment, retinoid therapy to hold around 40% market value share, globally, primarily due to its effectiveness in controlling the spread of acne as compared to other products and reducing the formation of acne scars.
- Based on route of administration, the topical route of administration is leading with over 60% of market share. Ease of application and greater availability of lotions, creams, and gels are positively driving demand for topical products.
- Inflammatory acne is estimated to dominate the market by type. This segment accounted for approximately 53% share of the market. Significant scarring and pain associated with this type of acne is a key factor driving the segment.
- Institutional sales dominate acne treatment with a market share of 52%. Growing number of dermatology clinics and rising preference toward office-based acne treatment procedures to achieve faster results have created a positive impact on the growth of the market.
- By region, North America is set dominate the global acne treatment market with a value share of around 44%.
Europe is slated to be the second-largest leading region with a value share of 20% during the forecast period.
“Growing prevalence of acne, preference toward use of combination treatments, and new product launches & approvals are expected to drive market growth over the coming years,” says an analyst of Persistence Market Research.
Buy this Report@ https://www.persistencemarketresearch.com/checkout/5279
Market Competition
New product launches and approvals, agreements, collaborations, and partnerships have emerged as the key growth strategy adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.
- In January 2021, Eligo Biosciences SA and GlaxoSmithKline PLC entered into a research collaboration to develop gene therapies to treat or prevent the growth of normal acne.
- In February 2020, Almirall S.A. entered into a licensing agreement with Paratek Pharmaceuticals, Inc. to expand Almirall’s Seysara in the market in China.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the acne Treatment market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.
The research study is based on the product (therapeutic treatment [antibiotics, retinoid therapy, hormonal drugs, anti-inflammatory drugs, and chemical peels] and devices [laser devices and radio frequency therapy]), route of administration (topical and oral), acne type (inflammatory and non-Inflammatory acne), distribution channel (institutional sales [hospitals and speciality clinics) and retail sales [retail pharmacies, drug stores, and online sales]), across seven key regions of the world.
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
